系统性红斑狼疮患者使用免疫抑制剂后卵巢贮备功能的临床评估_West China Medical Journal

Authors：

 刘潇潇 , 练颖

成都市第一人民医院血液风湿科（成都 610041）;

Corresponding author：

Keywords：

系统性红斑狼疮; 抗苗勒管激素; 卵巢贮备功能

DOI：

10.7507/1002-0179.20160081

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的研究抗苗勒管激素（AMH）与系统性红斑狼疮（SLE）女性患者使用免疫抑制剂的关系，评估SLE患者卵巢贮备功能。方法选取2009年1月-2013年12月72例年龄在18～40岁，符合美国风湿病学会诊断标准的初诊SLE女性患者，使用酶联免疫吸附测定法对患者用药前后血清中AMH进行检测，选取同期20例同年龄段健康女性作为正常对照。比较使用环磷酰胺（CTX）患者（A组，n=41）与未使用CTX患者（B组，n=31）血清AMH的差异，了解AMH水平与CTX累积剂量及年龄之间的关系。结果 72例SLE患者使用免疫抑制剂后血清中AMH水平[（2.39±1.12）ng/mL]较使用前[（3.12±1.38）ng/mL]及正常对照组[（2.95±0.86）ng/mL]低，差异均有统计学意义（P＜0.05）。治疗后A组患者血清中AMH水平[（2.24±1.23）ng/mL]低于治疗前[（2.97±1.31）ng/mL]，且低于B组患者血清中AMH水平[（2.92±0.82）ng/mL]，差异有统计学意义（P＜0.05）；B组治疗前差异无统计学意义（P＞0.05）。AMH水平与使用CTX累积剂量及年龄呈负相关（P＜0.05）。结论 AMH可以作为评价SLE女性患者在使用CTX后造成卵巢损伤的一个指标。

Citation： 刘潇潇, 练颖. 系统性红斑狼疮患者使用免疫抑制剂后卵巢贮备功能的临床评估. West China Medical Journal, 2016, 31(2): 306-308. doi: 10.7507/1002-0179.20160081 Copy

1.	Clowse ME, Harward L, Criscione-Schreiber L, et al. Anti-Müllerian hormone:a better marker of ovarian damage from cyclophosphamide[J]. Arthritis Rheum, 2012, 64(5):1305-1310.
2.	Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-Müllerian hormone and inhibin B in thedefinition of ovarian aging and the menopause transition[J]. J Clin Endoc Metab, 2008, 93(9):3478-3483.
3.	Visser JA, de Jong FH, Laven JS, et al. Anti-Müllerian hormone:a new marker for ovarian function[J]. Reproduction, 2006, 131(1):1-9.
4.	McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide[J]. Ann Rheum Dis, 1996, 55(4):224-229.
5.	Warne GL, Fairley KF, Hobbs JB, et al. Cyclophosphamide-induced ovarian failure[J]. N Engl J Med, 1973, 289(22):1159-1162.
6.	Petri M. Systemic Lupus International Collaborating Clinic (SLICC):SLICC revision of the ACR classification criteria for SLE[J]. Arthritis Rheum, 2009, 60(Suppl 10):895.
7.	Weenen C, Laven JS, von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary:potential implications forinitial and cyclic follicle recruitment[J]. Mol Hum Reprod, 2004, 10(2):77-83.
8.	Pigny P, Jonard S, Robert Y, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2006, 91(3):941-945.
9.	Mok CC, Chan PT, To CH. Anti-Müllerian hormone and ovarian reserve in systemic lupus erythematosus[J]. Arthritis Rheum, 2013, 65(1):206-210.
10.	李艳梅, 赵义, 慈春增, 等. 抗缪勒管激素在女性系统性红斑狼疮中的临床意义及与抗卵巢细胞抗体的关系[J]. 中华风湿病学杂志, 2010, 14(5):305-307.
11.	Lawrenz B, Henes JC, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reservein premenopausal women:evaluation by using anti-Müellerian hormone[J]. Lupus, 2011, 20 (11):1193-1197.

1. Clowse ME, Harward L, Criscione-Schreiber L, et al. Anti-Müllerian hormone:a better marker of ovarian damage from cyclophosphamide[J]. Arthritis Rheum, 2012, 64(5):1305-1310.
2. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-Müllerian hormone and inhibin B in thedefinition of ovarian aging and the menopause transition[J]. J Clin Endoc Metab, 2008, 93(9):3478-3483.
3. Visser JA, de Jong FH, Laven JS, et al. Anti-Müllerian hormone:a new marker for ovarian function[J]. Reproduction, 2006, 131(1):1-9.
4. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide[J]. Ann Rheum Dis, 1996, 55(4):224-229.
5. Warne GL, Fairley KF, Hobbs JB, et al. Cyclophosphamide-induced ovarian failure[J]. N Engl J Med, 1973, 289(22):1159-1162.
6. Petri M. Systemic Lupus International Collaborating Clinic (SLICC):SLICC revision of the ACR classification criteria for SLE[J]. Arthritis Rheum, 2009, 60(Suppl 10):895.
7. Weenen C, Laven JS, von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary:potential implications forinitial and cyclic follicle recruitment[J]. Mol Hum Reprod, 2004, 10(2):77-83.
8. Pigny P, Jonard S, Robert Y, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2006, 91(3):941-945.
9. Mok CC, Chan PT, To CH. Anti-Müllerian hormone and ovarian reserve in systemic lupus erythematosus[J]. Arthritis Rheum, 2013, 65(1):206-210.
10. 李艳梅, 赵义, 慈春增, 等. 抗缪勒管激素在女性系统性红斑狼疮中的临床意义及与抗卵巢细胞抗体的关系[J]. 中华风湿病学杂志, 2010, 14(5):305-307.
11. Lawrenz B, Henes JC, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reservein premenopausal women:evaluation by using anti-Müellerian hormone[J]. Lupus, 2011, 20 (11):1193-1197.

Previous Article
Analysis of Maternal and Infant Outcomes of Pregnant Women with Gestational Diabetes Mellitus
Next Article
三种自身抗体和补体C3水平检测对狼疮性肾炎患者的诊断意义

West China Medical Journal

系统性红斑狼疮患者使用免疫抑制剂后卵巢贮备功能的临床评估

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content